Table 1.
Patient characteristics for development and validation cohort.
| Characterstic | Development Cohort (n = 199) n (%) | Validation Cohort (n = 135) n (%) | |
|---|---|---|---|
| Histology | serous | 142 (71) | 113 (84) |
| non-serous | 57 (29) | 22 (16) | |
| FIGO | 1 | 36 (18) | 0 (0) |
| 2 | 7(4) | 8 (6) | |
| 3 | 119 (60) | 101 (75) | |
| 4 | 37 (19) | 26 (19) | |
| Histologic | NA | 2 (1) | 0 (0) |
| Grade | 1 | 11 (6) | 4 (3) |
| 2 | 81 (41) | 30 (22) | |
| 3 | 105 (53) | 101 (75) | |
| Residual | yes | 83 (42) | 38 (28) |
| Tumor | no | 113 (57) | 97 (72) |
| NA | 3 (2) | 0 (0) | |
| Age | ≤55 | 77 (39) | 58 (43) |
| >55 | 122 (61) | 77 (57) | |
| Median (range) | Median (range) | ||
| Age | 59 (18–88) | 57 (27–85) | |
FIGO: Fédération Internationale de Gynécology et d’Obstétrique; NA: not available.